LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)
Close on Nov 17, 2026Market cap $109.97MP/E –Yield –
LENZ Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
LENZ Therapeutics's price to book ratio was 0.6× on Nov 11, 2026, against 4.5× a year earlier. Over the last 4 years it ranged from 0.1× to 6.4×, with a median of 1.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.6× | −1.8 |
| 2025 | Dec 31, 2025 | 2.4× | −1.3 |
| 2024 | Dec 31, 2024 | 3.7× | +3.6 |
| 2023 | Jan 31, 2023 | 0.1× | −0.1 |
| 2022 | Dec 30, 2022 | 0.1× | −0.3 |
| 2021 | Dec 31, 2021 | 0.4× | – |
See a number that looks wrong?